Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Part of paid clinical trials in Miami, Florida.

Sponsor
University of Miami
Study ID
NCT03367871
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    IV
  • Paclitaxel — DRUG
    Administered intravenously (IV) on day 1
  • Cisplatin — DRUG
    Administered intravenously (IV) on day 1
  • Carboplatin — DRUG
    Administered intravenously (IV) on day 1
  • Bevacizumab — DRUG
    Administered intravenously (IV) on day 1

Study Details

The investigators propose to evaluate the efficacy of the combination of standard chemotherapy with bevacizumab with Pembrolizumab in women with recurrent, persistent, or metastatic cervical cancer.

Key Dates

First listed
Dec 11, 2017
Start date
Sep 6, 2018
Status verified
May 2024
Primary completion
Jan 30, 2023
Completion
Jan 30, 2023

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pembrolizumab, Chemotherapy, Bevacizumab
    On day 1 of each 21 day cycle, participants will be administered Pembrolizumab 200mg (IV); Chemotherapy including Paclitaxel 175mg/m2 or 135 mg/m2 (IV), and Cisplatin 50mg/m2 (IV) or Carboplatin area under the curve (AUC) 5; and Bevacizumab 15mg/kg (IV).

Primary Outcome Measure

Objective Response (OR) [ Time Frame: Up to 24 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of MiamiMiamiFlorida33136-

Find similar trials in Miami, FL

By condition
Cervical cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
University of Miami· Miami, FL

Related Studies